CJC-1295 · Ipamorelin · BPC-157 · TA-1 — Body Composition and Recovery
The complete performance optimisation protocol — combining dual GH axis stimulation (CJC-1295 + Ipamorelin) for body composition and recovery, targeted tissue healing (BPC-157) for injury prevention and repair, and immune restoration (TA-1) to counteract the T-cell suppression that elevated IGF-1 causes. Designed for athletes and active individuals seeking optimised performance, recovery and injury resilience.
The Performance Stack is designed around a fundamental insight — GH axis optimisation produces significant body composition and recovery benefits, but elevated IGF-1 suppresses T-cell immune surveillance. Without addressing this suppression, GH protocols carry increased risk of viral reactivation (HSV, VZV) and reduced immune resilience. The Performance Stack addresses the benefits and the risks simultaneously.
The dual GH secretagogue combination provides the foundation of the performance stack. CJC-1295 amplifies GH pulse amplitude through GHRH receptors while Ipamorelin triggers pulse timing through ghrelin receptors — together producing a significantly larger GH pulse than either compound alone. The resulting IGF-1 elevation drives lean muscle mass increase, enhanced fat oxidation, improved recovery from training, and better sleep quality through the amplified nocturnal GH pulse. Unlike exogenous HGH, this approach preserves the natural GH axis and avoids pituitary suppression.
Elevated training loads under GH optimisation increase the risk of tendon and ligament stress. BPC-157 addresses this proactively — its fibroblast migration and collagen remodelling properties maintain tendon and ligament integrity under increased mechanical load, and accelerate repair when micro-damage occurs. The combination of BPC-157 with a GH stack is synergistic — GH optimisation drives muscle growth and recovery while BPC-157 ensures the connective tissue adapts to keep pace.
TA-1 is the critical safety component of the performance stack. Elevated IGF-1 from GH stimulation suppresses CD8+ T-cell surveillance — the immune cells that keep latent viruses (HSV, VZV) dormant in nerve ganglia. Without immune support, GH protocols frequently trigger herpes reactivation in susceptible individuals. TA-1 directly restores CD8+ T-cell function, counteracting this suppression and allowing the GH stack to run cleanly without immune compromise.